Immunotherapy using WT1 peptide against recurrent glioblastoma multiforme: A phase I/II study.

Not Applicable

• Conditions: glioblastoma multiforme

• Registration Number: JPRN-UMIN000002024
• Lead Sponsor: Cancer Vaccination Therapy Research Network, Department of Immunology, Kochi Medical School

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-06-01
• Study Completion: 2014-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

The following patients must be excluded: 1) Patients with uncontrollable infectious disease (including active Tuberculosis). 2) Patients with severe symptoms (malignant hypertension, severe congestive heart failure, severe colonary insufficiency, Myocardial Infarction within three months lately, terminal phase liver cirrhosis, uncontrollable Diabetes Mellitus, severe Pulmonary Fibrosis, active interstitial pneumonia, etc.). 3) Patients previously treated with Allogeneic bone marrow transplantation. 4) Patients who are pregnant and/or breast feeding, 5) Patients with severe psychiatric disease. 6) Patients who participate in any other clinical trial. 7) Patients who previously participated in this clinical trial. 8) Any patients disqualified by a study physician because of medical, psychological, or any other factors.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of side effects (phase I) Progression-free survival (phase II)

Secondary Outcome Measures

Name	Time	Method
Disease control rate, survival rate, overall survival, Objective response rate, adverse events, immunological responses